2 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow Anaveon AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1) ANV600, ANV600 + pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Anaveon AG | 63 | 2024-07-01 | 2026-07-10 |
| A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). ANV419 - Melanoma (Skin), Cutaneous Melanoma | Phase 1 / Phase 2 | Completed | Anaveon AG | 29 | 2022-12-16 | 2025-08-26 |
Disease (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1)
pembrolizumab (1)
France (2) · Germany (2) · Spain (2) · United States (2) · Belgium (1) · Italy (1) · Netherlands (1) · Switzerland (1)
Eduard Gasal, MD (1)
2023 (1)